BOULDER, Colo., Dec. 6 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) reported today that data from 36 abstracts of studies investigating the company's marketed and pipeline hematology products will be presented at the American Society of Hematology's (ASH) 49th Annual Meeting and Exposition in Atlanta (December 8-11, 2007). These abstracts include summaries of data from studies of several key products in the company's commercial and development portfolio for a variety of indications, including Myelodysplastic Syndromes (MDS), acute myeloid leukemia (AML), multiple myeloma (MM), Hodgkin's lymphoma (HL), and two forms of non-Hodgkin's lymphoma (NHL).
"ASH promises to be a very exciting meeting for us, with a focus on the detailed presentation of data from the Vidaza overall survival study, which demonstrate an unprecedented survival benefit compared to conventional care regimens, as well as other compelling study data on Vidaza, Thalidomide and MGCD0103," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "The data from 36 abstracts, including 23 posters and 13 oral presentations, to be presented demonstrates the progress of our pipeline and we are very enthusiastic about our participation this year."
Studies presented at this year's ASH meeting will report the complete Phase 3 data set from a study demonstrating that Vidaza(R) (azacitidine for injection) provides a significant survival benefit beyond that provided by conventional care regimens for higher-risk MDS patients. Other data to be presented at the meeting include alternate dosing schedules of Vidaza and the use of Vidaza as a maintenance therapy for patients with higher-risk MDS and AML.
Additionally, data from a study of Vidaza in combination with MGCD0103 in MDS and AML will be presented at ASH, as will poster presentations featuring study results from two ongoing single-agent Phase 2 MGCD0103 trials, one in refractory/relapsed classical HL patients and the other in diffuse large B cell lymphoma and follicular lymphoma, two forms of NHL.
"The data on Pharmion's products being presented at ASH clearly demonstrate the importance of epigenetic therapy in the treatment of hematologic malignancies and Pharmion's leadership position in the field of epigenetics," said Andrew R. Allen, chief medical officer of Pharmion. "In particular, the data being presented confirming the clinical responses with Vidaza, MGCD0103 and their combination suggest a promising synergistic treatment approach using epigenetic therapies."
Pharmion's portfolio of epigenetic therapies includes three developmental programs: Vidaza and oral azacitidine, both DNA demethylating agents; MGCD0103, a HDAC inhibitor; and sirtuin inhibitors, Pharmion's newest epigenetic research program. Pharmion currently markets Vidaza, the parenteral formulation of Azacitidine, in the U.S. and several additional countries for the treatment of patients with MDS, and as previously mentioned the full data set from the Phase 3 study of Vidaza's effect on overall survival in higher-risk MDS patients will be presented at the meeting.
Data from a study evaluating the addition of Thalidomide to front-line melphalan/prednisone (MP) therapy in newly diagnosed elderly patients with multiple myeloma will be the subject of an oral presentation at ASH, where two oral presentations and three posters on Thalidomide studies will be presented.
The following data will be presented during the 49th Annual ASH Meeting and Exposition:
Vidaza(R)
Date / Time / Location: December 11, 2007; 7:30-9:00 a.m., Thomas B Murphy Ballroom 4, Georgia World Congress Center
Date / Time / Location: December 8, 2007; Viewing 9:00 a.m.-7:30 p.m., Presentation 5:30 -7:30 p.m., Hall B4 of Georgia World Congress Center
Date / Time / Location: December 8, 2007; Viewing 9:00 a.m.-7:30 p.m., Presentation 5:30-7:30 p.m., Hall B4 of Georgia World Congress Center
Date / Time / Location: December 8, 2007; Viewing 9:00 a.m.-7:30 p.m., Presentation 5:30-7:30 p.m., Hall B4 of Georgia World Congress Center
Session: Myelodysplastic Syndromes: Clinical Studies, Including Transplantation
Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Session: Myelodysplastic Syndromes: Prognosis and Clinical Correlative Studies
Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Date / Time / Location: December 10, 2007; 1:30-3:00 p.m., Rooms B216-B217, Georgia World Congress Center
Date / Time / Location: December 10, 2007; 1:30-3:00 p.m., Rooms A411-A412, Georgia World Congress Center
Session: Acute Myeloid Leukemias: Therapy, Excluding Transplantation-Novel Therapies
Date / Time / Location: December 10, 2007; Viewing 10:30 a.m.-7:00 p.m., Presentation 5:00-7:00 p.m., Hall B4 of Georgia World Congress Center
Session: Clinical Care: Transplantation Regimen Toxicities and Engraftment II
MGCD0103
Date / Time / Location: December 9, 2007; Viewing 6:00 p.m.-8:00 p.m., Presentation 6:00 p.m., Hall B4 of Georgia World Congress Center
Date / Time / Location: December 10, 2007; 1:30-3:00 p.m., Rooms A411-A412, Georgia World Congress Center
Session: Acute Myeloid Leukemias: Therapy, Excluding Transplantation-Novel Therapies
Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Thalidomide
Date / Time / Location: December 9, 2007; 4:30-6:00 p.m.; Rooms C303-C305, Georgia World Congress Center
Date / Time / Location: December 10, 2007; 7:30-9:00 a.m.; Rooms C303-C305, Georgia World Congress Center
Date / Time / Location: December 10, 2007; 1:30-3:00 p.m.; Rooms C306-C308, Georgia World Congress Center
Session: Autologous Transplantation for Myeloma: Induction, Mobilization, and Biologic Correlates
Date / Time / Location: December 10, 2007; 1:30-3:00 p.m.; Rooms C303-C305, Georgia World Congress Center
Session: Myeloma: Maintenance, Consolidation and Bone Disease in Multiple Myeloma
Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Date / Time / Location: December 10, 2007; Viewing 10:30 a.m.-7:00 p.m., Presentation 5:00-7:00 p.m., Hall B4 of Georgia World Congress Center
About Pharmion
Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, including summary statements relating to the interim or preliminary results of clinical trials involving Vidaza, Thalidomide Pharmion, and MGCD0103. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results summarized by such statements. Preliminary results may not be confirmed upon final analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of Pharmion's products may be discovered upon further analysis of clinical trial data and upon review and analysis of additional clinical trial data from this or other clinical trials. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in Pharmion's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Pharmion also disclaims any duty to comment upon or correct information that may be contained in reports published by the investment community.
SOURCE Pharmion Corporation
